K00135 | CAS#869650-21-5 | PIM kinase inhibitor

MedKoo Cat#: 558243 | Name: K00135

Description:

WARNING: This product is for research use only, not for human or veterinary use.

K00135 is a potent and selective inhibitor of PIM kinases. K00135 was shown to impair survival and clonogenic growth of a panel of human acute leukemia cells. Exposure to K00135 also significantly suppressed in vitro growth of leukemic blasts from five acute myelogenous leukemia patients but not of normal umbilical cord blood mononuclear cells.

Chemical Structure

K00135

CAS#869650-21-5

Theoretical Analysis

MedKoo Cat#: 558243

Name: K00135

CAS#: 869650-21-5

Chemical Formula: C18H18N4O

Exact Mass: 306.1481

Molecular Weight: 306.36

Elemental Analysis: C, 70.57; H, 5.92; N, 18.29; O, 5.22

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

K00135; K-00135; K 00135;

IUPAC/Chemical Name

1-[3-[6-[(Cyclopropylmethyl)amino]imidazo[1,2-b]pyridazin-3-yl]phenyl]-ethanone

InChi Key

IVUBNTNWKIPCPS-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H18N4O/c1-12(23)14-3-2-4-15(9-14)16-11-20-18-8-7-17(21-22(16)18)19-10-13-5-6-13/h2-4,7-9,11,13H,5-6,10H2,1H3,(H,19,21)

SMILES Code

CC(C1=CC=CC(C2=CN=C3C=CC(NCC4CC4)=NN32)=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 306.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Darby RA, Unsworth A, Knapp S, Kerr ID, Callaghan R. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors. Cancer Chemother Pharmacol. 2015 Oct;76(4):853-64. doi: 10.1007/s00280-015-2858-9. Epub 2015 Sep 9. PubMed PMID: 26351135. 2: Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, Bhattacharya B, Lim KH, Soong R, Yeoh KG, Deng N, Tan P, Lam Y, Salto-Tellez M; Singapore Gastric Cancer Consortium. Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer. 2012 Apr;15(2):188-97. doi: 10.1007/s10120-011-0097-2. Epub 2011 Oct 13. PubMed PMID: 21993851. 3: Pogacic V, Bullock AN, Fedorov O, Filippakopoulos P, Gasser C, Biondi A, Meyer-Monard S, Knapp S, Schwaller J. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res. 2007 Jul 15;67(14):6916-24. PubMed PMID: 17638903. 4: Taparowsky EJ, Gerbi SA. Structure of 1.71 lb gm/cm(3) bovine satellite DNA: evolutionary relationship to satellite I. Nucleic Acids Res. 1982 Sep 25;10(18):5503-15. PubMed PMID: 6292843; PubMed Central PMCID: PMC320891.